BC Week In Review | Oct 20, 2014
Company News

Cognoptix board of directors update

Cognoptix Inc. , Acton, Mass.   Business: Diagnostic, Supply/Service   Appointed: President and CEO Paul Hartung as chairman  ...
BC Week In Review | Oct 6, 2014
Financial News

Cognoptix completes venture financing

Cognoptix Inc. , Acton, Mass.   Business: Diagnostic, Supply/Service   Date completed: 2014-09-30   Type: Venture financing   Raised: $15 million   Investors: Alopexx Enterprises LLC; Inventages Venture Capital; Launchpad Venture Group   Note: The company...
BC Week In Review | Oct 7, 2013
Clinical News

SAPPHIRE II eye test: Pilot trial data

A pilot trial showed that the SAPPHIRE II eye test had 85% sensitivity and 95% specificity for differentiating 20 patients who were clinically diagnosed with probable AD from 20 age-matched healthy controls. Data will be...
BC Week In Review | Mar 11, 2013
Clinical News

SAPPHIRE II eye test: Pilot trial started

Cognoptix said it began a pilot trial to evaluate its SAPPHIRE II eye test in 40 patients. Data from a pilot trial showed that SAPPHIRE II produced 2-fold higher scores in subjects with probable AD...
BC Week In Review | Jan 14, 2013
Clinical News

SAPPHIRE II eye test: Pilot trial data

Top-line data from an open-label pilot trial in 5 subjects aged 31-77 years with no evidence of cognitive impairment and 5 subjects aged 65-83 years that met acceptable standards for probable AD showed that Cognoptix's...
BC Week In Review | Dec 17, 2012
Company News

Cognoptix, University of California deal

The university granted Cognoptix (formerly Neuroptix Corp. ) exclusive, worldwide rights to develop and commercialize color-coded markers of beta amyloid . Cognoptix uses the technology in its SAPPHIRE II non-invasive diagnostic for early diagnosis of Alzheimer's disease...
BC Week In Review | Jan 17, 2011
Financial News

Neuroptix completes venture financing

Neuroptix Corp. , Acton, Mass.   Business: Diagnostic, Supply/Service   Date completed: 1/10/11   Type: Venture financing   Raised: $4 million   Investor: Inventages Venture Capital   Note: The financing is the first tranche of a...
BC Week In Review | Dec 22, 2008
Company News

Neuroptix management update

Neuroptix Corp. , Acton, Mass.   Business: Diagnostic, Supply/Service   Hired: Gerald Cagle as COO, formerly SVP of R&D and CSO at Alcon Inc. subsidiary Alcon Laboratories, Inc.  ...
BC Extra | Oct 23, 2008
Financial News

Neuroptix raises $18.5 million

Neuroptix (Acton, Mass.) raised $18.5 million in a series B round led by new investor Inventages Venture Capital. Rockport Venture advised Neuroptix . The company is developing Neuroptix Sapphire to detect Alzheimer's disease (AD). The non-invasive...
BC Week In Review | Feb 4, 2008
Company News

Neuroptix board of directors update

Neuroptix Corp. , Acton, Mass.   Business: Diagnostic, Supply/Service   Appointed: Michael Henry, VP of business development at Athena Diagnostics Inc. ; and Stephen DiPalma, CFO of Rxi Pharmaceuticals Corp.  ...
Items per page:
1 - 10 of 14
BC Week In Review | Oct 20, 2014
Company News

Cognoptix board of directors update

Cognoptix Inc. , Acton, Mass.   Business: Diagnostic, Supply/Service   Appointed: President and CEO Paul Hartung as chairman  ...
BC Week In Review | Oct 6, 2014
Financial News

Cognoptix completes venture financing

Cognoptix Inc. , Acton, Mass.   Business: Diagnostic, Supply/Service   Date completed: 2014-09-30   Type: Venture financing   Raised: $15 million   Investors: Alopexx Enterprises LLC; Inventages Venture Capital; Launchpad Venture Group   Note: The company...
BC Week In Review | Oct 7, 2013
Clinical News

SAPPHIRE II eye test: Pilot trial data

A pilot trial showed that the SAPPHIRE II eye test had 85% sensitivity and 95% specificity for differentiating 20 patients who were clinically diagnosed with probable AD from 20 age-matched healthy controls. Data will be...
BC Week In Review | Mar 11, 2013
Clinical News

SAPPHIRE II eye test: Pilot trial started

Cognoptix said it began a pilot trial to evaluate its SAPPHIRE II eye test in 40 patients. Data from a pilot trial showed that SAPPHIRE II produced 2-fold higher scores in subjects with probable AD...
BC Week In Review | Jan 14, 2013
Clinical News

SAPPHIRE II eye test: Pilot trial data

Top-line data from an open-label pilot trial in 5 subjects aged 31-77 years with no evidence of cognitive impairment and 5 subjects aged 65-83 years that met acceptable standards for probable AD showed that Cognoptix's...
BC Week In Review | Dec 17, 2012
Company News

Cognoptix, University of California deal

The university granted Cognoptix (formerly Neuroptix Corp. ) exclusive, worldwide rights to develop and commercialize color-coded markers of beta amyloid . Cognoptix uses the technology in its SAPPHIRE II non-invasive diagnostic for early diagnosis of Alzheimer's disease...
BC Week In Review | Jan 17, 2011
Financial News

Neuroptix completes venture financing

Neuroptix Corp. , Acton, Mass.   Business: Diagnostic, Supply/Service   Date completed: 1/10/11   Type: Venture financing   Raised: $4 million   Investor: Inventages Venture Capital   Note: The financing is the first tranche of a...
BC Week In Review | Dec 22, 2008
Company News

Neuroptix management update

Neuroptix Corp. , Acton, Mass.   Business: Diagnostic, Supply/Service   Hired: Gerald Cagle as COO, formerly SVP of R&D and CSO at Alcon Inc. subsidiary Alcon Laboratories, Inc.  ...
BC Extra | Oct 23, 2008
Financial News

Neuroptix raises $18.5 million

Neuroptix (Acton, Mass.) raised $18.5 million in a series B round led by new investor Inventages Venture Capital. Rockport Venture advised Neuroptix . The company is developing Neuroptix Sapphire to detect Alzheimer's disease (AD). The non-invasive...
BC Week In Review | Feb 4, 2008
Company News

Neuroptix board of directors update

Neuroptix Corp. , Acton, Mass.   Business: Diagnostic, Supply/Service   Appointed: Michael Henry, VP of business development at Athena Diagnostics Inc. ; and Stephen DiPalma, CFO of Rxi Pharmaceuticals Corp.  ...
Items per page:
1 - 10 of 14